C17orf75 Inhibitors

C17orf75 can contain PI3K inhibitors like Wortmannin and LY294002 prevent the phosphorylation and activation of downstream proteins in the AKT pathway. Similarly, mTOR inhibitors like Rapamycin can suppress cell growth and proliferation, which could indirectly affect proteins that interact with or are regulated by the mTOR pathway. Inhibitors targeting the MAPK/ERK pathway, such as PD98059 and U0126, are designed to block the phosphorylation of MEK, thereby inhibiting the activation of ERK and affecting downstream protein function. Inhibitors like SB203580, SP600125, and Y-27632 target other kinases involved in stress responses, apoptosis, and cytoskeletal organization, potentially altering the function of proteins associated with these processes.

Small molecules like Gefitinib and Dasatinib inhibit specific tyrosine kinases, which can influence various cellular processes, including cell division, apoptosis, and differentiation. HDAC inhibitors like Trichostatin A can alter gene expression profiles, impacting protein synthesis and function. Proteasome inhibitors such as Bortezomib disrupt the degradation of cellular proteins, leading to effects on cell cycle and stress response proteins.